ATRYS HEALTH, S.A. Inactive Instrument
Atrys Health, S.A. Share Price BME
Equities
ES0105148003
Healthcare Facilities & Services
| Sales 2024 * | 223M 238M 19.02B | Sales 2025 * | 240M 256M 20.46B | Capitalization | 212M 226M 18.09B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | 8M 8.55M 683M | EV / Sales 2024 * | 1.65 x |
| Net Debt 2024 * | 155M 166M 13.26B | Net Debt 2025 * | 121M 129M 10.33B | EV / Sales 2025 * | 1.39 x |
| P/E ratio 2024 * |
-64.7
x | P/E ratio 2025 * |
24.3
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 48.57% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 12/06/07 | |
| Director of Finance/CFO | - | 31/07/15 | |
| Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 48 | 31/01/16 | |
| Director/Board Member | 69 | - | |
| Director/Board Member | - | - |
Atrys Health SA, formerly Europath Biosciences SL, is Spain-based company primarily engaged in the predictive and personalized oncology therapies. It operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. It has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The Company has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.45% | 85.02B | |
| +14.02% | 82.37B | |
| +9.37% | 29.29B | |
| -10.34% | 17.21B | |
| -0.36% | 16.7B | |
| +0.74% | 15.5B | |
| +4.32% | 12.15B | |
| -2.34% | 12.13B | |
| +31.86% | 12.12B |
